QuidelOrtho Corporation

QuidelOrtho Corporation provides diagnostic testing solutions through its Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The company offers clinical chemistry laboratory instruments and tests, immunoassay instruments and tests, and specialized diagnostic solutions. The Transfusion Medicine unit provides immunohematology instruments and tests for blood typing and donor screening. The Point-of-Care unit offers instruments and tests for rapid results in various settings. The Molecular Diagnostics unit provides polymerase chain reaction thermocyclers, amplification systems, and sample-to-result molecular instruments and tests. The company sells its products directly to end users and through distributors internationally.

Overview

Sector

Medical Devices

Target Price

0.0 USD

Current Price

27.9 USD

Potential

-100%

Strengths

Price to book ratio (0.65) is lower than the sector mean (13.90).
EV/EBITDA (8.80) is lower than the sector mean (222.25).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (4.85) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (1.52%) is significantly lower than the sector mean (2.97%).
EV/EBIT (100.00) is significantly higher than the sector mean.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	8.7
Price/Free Cash Flow'	100.0
ROIC	1.5%
Net Debt/EBITDA	4.9